Psychedelics closer to commercialization; Compass far and away the leader

Analyst Alex Carchidi discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). Cybin and Atai developments; clinical studies and regulatory relief (5:25). Why now is the time to get into the space; ranking Compass and MindMed above the rest (8:00). Proper metrics and diversified pipelines (10:20).<br /><br />Show Notes:<br />Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment<br />De-Risking Psychedelics: Compass Pathways, Cybin And Atai<br />Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.<br />COMPASS Pathways Q1 2024 Earnings Call Transcript<br /><br />Episode transcripts<br /><br />For full...